Associations Between Family Members' Perceptions of the Health Care System and the Health of Youths with Insulin-Dependent Diabetes Mellitus

1988 ◽  
Vol 13 (4) ◽  
pp. 543-554 ◽  
Author(s):  
Cindy L. Hanson ◽  
Scott W. Henggeler ◽  
Michael A. Harris ◽  
Kelly A. Mitchell ◽  
Deborah L. Carle ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Health Care ◽  
Health Care System ◽  
Family Members ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Insulin Dependent ◽  
Care System

scholarly journals Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus.

1992 ◽  
Vol 3 (4) ◽  
pp. S111
Author(s):  
J E Siegel ◽  
A S Krolewski ◽  
J H Warram ◽  
M C Weinstein
Keyword(s):  
Diabetes Mellitus ◽  
Health Care ◽  
Cost Effectiveness ◽  
Early Treatment ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Future Research ◽  
Improve Life Expectancy ◽  
Insulin Dependent

Studies have demonstrated that "antihypertensive" treatment with angiotensin-converting enzyme inhibitors (ACEI) may retard the progress of nephropathy in patients with insulin-dependent diabetes mellitus. To obtain an indication of the potential effect of ACEI treatment and as a guide to future research, the effects of screening and early ACEI treatment programs were estimated using cost-effectiveness models. The preliminary analysis suggests that the early treatment of insulin-dependent diabetes mellitus patients with ACEI is likely to be a very cost-effective use of health care resources. The cost-effectiveness ratio for screening and treatment at the stage of microalbuminuria ($7,900 to $16,500 per year of life saved) compares favorably with those of other medical life-saving interventions. Less-aggressive programs (screening followed by treatment at the stage of proteinuria) would improve life expectancy to a lesser extent but could save net health care costs as well as years of life. Although more exact and comprehensive cost-effectiveness analysis must await clinical trials, these illustrative results demonstrate the range of cost-effectiveness that can be expected from these programs and identify data needed for more decisive policy conclusions.

Sign in / Sign up

Export Citation Format

Share Document